<DOC>
	<DOCNO>NCT00482391</DOCNO>
	<brief_summary>The purpose study study new treatment HER-2/neu ( + ) breast cancer .</brief_summary>
	<brief_title>Doxorubicin Cyclophosphamide Followed Paclitaxel , Trastuzumab , Lapatinib Treating Patients With HER2/Neu-Overexpressed Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Bilateral synchronous breast tumor allow Any nodal status tumor size allow No stage IV disease HER2/neupositive disease 3+ IHC OR FISHamplified Hormone receptor status specify PATIENT CHARACTERISTICS : Male female Menopausal status specify ECOG performance status 01 Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.1 mg/dL SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception completion study therapy LVEF ≥ 50 % MUGA scan No peripheral neuropathy &gt; grade 1 No active second malignancy within past 5 year except adequately treat nonmelanoma skin cancer situ carcinoma cervix No known allergy hypersensitivity doxorubicin hydrochloride , cyclophosphamide , paclitaxel , drug formulate Cremophor EL No psychiatric illness concurrent medical condition would preclude study treatment No condition , include follow : Unstable angina Congestive heart failure Myocardial infarction within past 12 month Highrisk uncontrolled arrhythmia ( e.g. , ventricular tachycardia , highgrade AV block , supraventricular arrhythmia adequately control ) No QT prolongation ( &gt; 500 m ) No active unresolved infection No sensitivity E. coli derive protein PRIOR CONCURRENT THERAPY : Prior hormonal therapy chemoprevention allow No prior trastuzumab ( Herceptin® ) No prior anthracyclines No concurrent hormonal therapy , include hormonal contraception ( e.g. , birth control pills ovarian hormonal replacement therapy ) No concurrent chemotherapy , radiotherapy , immunotherapy , biotherapy breast cancer No concurrent drug may prolong QT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>